COMPANY PROFILE

Arstrogen

Explore full profile

Innovative drug development for autism, enhancing patient well-being through clinical expertise

Daegu, South KoreaFounded 2017Biotech & Life Sciences

Valuation $100–250M Last recorded · 2023

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Arstrogen

Astrogen is a pioneering company in the pharmaceutical industry, focusing on innovative drug development specifically for autism. The company leverages extensive clinical experience and patient needs to create groundbreaking treatments that go beyond traditional therapy. Astrogen serves a niche market of healthcare providers and patients dealing with autism, aiming to improve their quality of life. The business operates on a research and development model, investing heavily in clinical trials and scientific research to bring new drugs to market. Revenue is generated through the commercialization of these drugs, partnerships with healthcare institutions, and potential licensing deals. Astrogen's commitment to innovation and patient well-being positions it as a key player in the specialized field of autism treatment.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2017
Headquarters: Daegu, South Korea
Open positions: None listed
Dealroom signal: 20.3/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VC✓Equity / VC	Nov 2023	$1.7M	$113M	Korea Pharma	↗
SERIES B✓Equity / VC	Jan 2022	$23M	$91M	IBK Capital · IBK Securities · BSK Investment	—

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Arstrogen website traffic

Latest recorded traffic for Arstrogen is 2.2K monthly website visits, down 46.3% over the last three months.

Latest monthly visits2.2K 3-month web change-46.3%

Monthly website visitsOct 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ADAdelaADELA \| A breakthrough approach to early detection	Toronto, Canada	Operational	69	$108M	$300M
FDForesight DiagnosticsProviding a sensitive liquid biopsy minimal residual disease (mrd) test to detect cancer	Boulder, United States	Acquired
ACAcepodiaAcepodia \| Simply Effective Breakthrough Therapies	Alameda, United States	Operational
TTTransCode TherapeuticsDelivering on the promise of RNAi therapeutics to defeat cancer	Boston, United States	Operational
BBBlueSphere BioNovel TCXpress technology to unlock the potential of personalized T-cell therapy for the treatment of cancer	Pittsburgh, United States	Operational
NSNuView Life SciencesPrecision cancer diagnostics and therapeutics	Park City, United States	Operational
BBBrightPath BiotherapeuticsStage biopharmaceutical company focused on developing novel cancer immunotherapies	Kawasaki, Japan	Operational
STSynendos TherapeuticsDeveloped first-in-class endocannabinoid modulators to restore natural functioning of the brain in CNS disorders	Basel, Switzerland	Operational